Algert Global LLC Invests $646,000 in Humana Inc. $HUM

Key Points

• Algert Global LLC has acquired 2,440 shares of Humana Inc. in Q1, valued at around $646,000, as reported in their latest 13F filing.
• Institutional investors own 92.38% of Humana's shares, with several firms like Raymond James and American Century increasing their positions significantly during the same quarter.
• Humana's quarterly earnings showed a reported EPS of $6.27, missing estimates, while the company also announced a quarterly dividend of $0.885 to be paid on October 31st.

Algert Global LLC bought a new position in Humana Inc. (NYSE:HUM - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 2,440 shares of the insurance provider's stock, valued at approximately $646,000.

Other large investors have also modified their holdings of the company. Cary Street Partners Investment Advisory LLC boosted its position in Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after purchasing an additional 46 shares in the last quarter. Riverview Trust Co purchased a new position in shares of Humana in the first quarter worth about $34,000. Garde Capital Inc. acquired a new position in Humana in the first quarter valued at approximately $36,000. Zions Bancorporation National Association UT acquired a new position in Humana in the first quarter valued at approximately $37,000. Finally, Whipplewood Advisors LLC increased its position in shares of Humana by 639.1% in the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock valued at $45,000 after buying an additional 147 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Price Performance

Shares of NYSE HUM traded up $2.13 during trading on Thursday, reaching $299.39. The company had a trading volume of 563,654 shares, compared to its average volume of 1,705,483. The stock has a market capitalization of $36.01 billion, a PE ratio of 22.99, a price-to-earnings-growth ratio of 1.76 and a beta of 0.44. The stock has a 50-day moving average price of $252.05 and a two-hundred day moving average price of $254.08. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $382.72. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, September 26th. Humana's dividend payout ratio is presently 27.17%.

Analyst Ratings Changes

Several brokerages recently commented on HUM. Robert W. Baird dropped their price target on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research report on Friday, July 25th. Morgan Stanley decreased their price target on Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Barclays set a $275.00 price target on Humana and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Oppenheimer increased their target price on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research note on Thursday, May 1st. Finally, Piper Sandler reduced their price target on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research report on Thursday, July 31st. Seven research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $283.29.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.